Skip to content
Daiichi Sankyo
-
Daiichi Sankyo sells healthcare division to Suntory for USD1.6B in three phases
For Daiichi Sankyo, divesting this business allows the company to concentrate resources on its innovative medicines division, where it has emerged as a leader in antibody-drug conjugate (ADC) technology.
-
China approves Daiichi Sankyo/AstraZeneca’s Enhertu for advanced gastric cancer
The approval specifically targets patients who have already undergone one prior trastuzumab-based treatment regimen.